Best phaco disinfection techniques

Article

Three-day application of levofloxacin in the presence of polyvinyl alcohol-iodine or povidone iodine offers the best infection control in phaco patients, according to a study published in the May 2008 issue of the Japanese Journal of Ophthalmology.

Three-day application of levofloxacin in the presence of polyvinyl alcohol-iodine or povidone iodine offers the best infection control in phaco patients, according to a study published in the May 2008 issue of the Japanese Journal of Ophthalmology.

Yoshitsugu Inoue of the Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University Yonago, Tottori, Japan and colleagues assessed preoperative disinfection methods to determine which method encouraged optimal duration of levofloxacin (LVFX), comparing povidone-iodine (PI) solution with polyvinyl alcohol-iodine (PAI), in elderly patients undergoing phacoemulsification aspiration and intraocular lens (IOL) implantation (n=272).

Subjects were randomized into six groups: three groups received three-day, one-day and one-hour preoperative applications of LVFX with PI eye wash, respectively; the remaining three groups received three-day, one-day and one-hour preoperative applications of LVFX with PAI eye wash, respectively. Subjects' corneas were scraped before and after LVFX application, after eyewash application and after surgery. Aqueous humour samples were also collected postoperatively.

The researchers found that, across all groups, three-day LVFX application was the more effective disinfectant method and PAI had a marginally higher rate of disinfection than PI: 79.4% and 78.0%, respectively. After LVFX and PAI/PI application, however, new isolates were detected.

The team concluded that, preoperatively, the best disinfection method is three-day application of LVFX with either PAI or PI solution, although it is unlikely that these disinfectants will eliminate bacteria entirely.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.